Hexa Reports -Geriatric Medicine Treat Age-Related Diseases Industry Report Review

Hexa Reports

Market Research Reports and Insightful Company Profiles

Geriatric Medicine Treat Age-related Diseases Market

Share, Size, Trends, Growth, Analysis and Outlook

Research Report by Hexa Reports

More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer

from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This

significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of

emergency admissions in elderly people is drug-related.

Browse Detail Report With TOC @ http://www.hexareports.com/report/geriatric-medicinedevelopment-carving-out-new-opportunities-to-treat-age-related-diseases/details

There remains a lack of clinical data to support prescription decisions as relatively few medicines have

been clinically evaluated in age-appropriate patients. In addition, many drugs are not available in

formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic

efficacy. In 2011, the EMA introduced its Geriatric Medicines Strategy to ensure that the medical

requirements of older people are identified earlier in the drug development process. In 2012, the ICH E7

guidelines were revised to include a greater focus on involving more geriatric patients in drug trials.

Request A Sample copy of This Report @ http://www.hexareports.com/sample/89659

Scope

- Reviews the current regulatory landscape and helps sponsors to understand the potential impact of

recent guidelines.

- Assesses the barriers to entry in geriatric medicines and identifies potential ways to overcome them

and improve clinical decision making.

Hexa Reports

Market Research Reports and Insightful Company Profiles

- Evaluates the importance of establishing Target Quality Product Profiles (TQPP) to help sponsors

determine the target patient population earlier on in drug development.

- Identifies treatment gaps and commercial...